Abstract

Objective Circular RNAs (circRNAs) have been reported to be widely involved in pathological processes of various cancers. However, little is known about their diagnostic values in early gastric cancer (EGC). This study is aimed at exploring whether circulating circRNAs in plasma could act as biomarkers for EGC diagnosis. Materials and Methods Mass spectrometry (MS) was performed to identify the proteins that at significantly aberrantly levels in gastric cancer (GC) tissues. The target circRNA was identified by bioinformatics analysis. A receiver operating characteristic (ROC) curve was generated to evaluate the diagnostic utility. Results MS revealed that the ribosomal protein L6 (RPL6) expression was significantly downregulated only in EGC tissues vs. nontumorous tissues; this was validated by western blotting (n = 30, p = 0.0094). Bioinformatics analysis predicted that there is a hsa_circ_0006848/hsa_miR-329-5p/RPL6 axis in GC progression. The hsa_circ_0006848 expression was significantly downregulated in EGC tissues (vs. nontumorous tissues, n = 30, p = 0.0073) and plasma samples from EGC patients (vs. paired healthy volunteers, n = 30, p = 0.0089). In addition, the hsa_circ_0006848 plasma level in postoperative patients was significantly higher than that of preoperative patients (n = 30, p = 0.047). Furthermore, the decreased hsa_circ_0006848 expression in plasma was negatively correlated with poor differentiation (p = 0.037) and tumor size (p = 0.046). The area under the ROC curve (AUC) of hsa_circ_0006848 in plasma was 0.733, suggesting a good diagnostic value. The plasma hsa_circ_0006848 level combined with the carcinoembryonic antigen (CEA), carbohydrate-associated antigen 19-9 (CA19-9), and carbohydrate-associated antigen 72-4 (CA72-4) level increased the AUC to 0.825. Conclusion Our results indicated that plasma hsa_circ_0006848 may be a novel noninvasive biomarker in EGC diagnosis.

Highlights

  • Gastric cancer (GC) is one of the major causes of cancerassociated mortality worldwide [1]

  • Gastric endoscopy is widely used for the early detection of gastric cancer (GC); it is worth noting that gastroscopic diagnosis of Early gastric cancer (EGC) is difficult and the gastroscopic results depend on the skills and consciousness of the endoscopists, because lesion of EGC is very subtle so that it may be missed during gastroscopy [5]

  • Proteins Identified in T1 Stage or Non-T1 Stage (T2-T4 Stage) in Gastric Cancer Samples and Ingenuity Pathway Analysis (IPA)

Read more

Summary

Introduction

Gastric cancer (GC) is one of the major causes of cancerassociated mortality worldwide [1]. According to the results of the 2009 annual report of the Japanese Gastric Cancer Association (JGCA) nationwide registry, the 5-year survival rate of advanced gastric cancer is still very poor; the 5-year survival rate of patients with EGC after surgical treatment has over 90% [3]. Gastric endoscopy is widely used for the early detection of GC; it is worth noting that gastroscopic diagnosis of EGC is difficult and the gastroscopic results depend on the skills and consciousness of the endoscopists, because lesion of EGC is very subtle so that it may be missed during gastroscopy [5]. Discovering novel biomarkers to improve the detection of EGC is urgently in demand

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call